When it comes to managing a severe chronic disease, how far should doctors push patients?

I was taken aback when a new patient showed me the fistfuls of paper towels he wedged into his underwear each day to absorb the pus draining from small openings across his groin. He had been doing this for years.

My patient, who was in his 20s, was living with a severe form of a difficult-to-treat disease called hidradenitis suppurativa (HS). It’s a chronic inflammatory condition that targets the folds of the body, especially in the buttocks, groin, and armpits, excavating little connections under the skin called sinus tracts and fistulas. These fill with fluid, become tender, and drain pus for days, weeks, even months or years.

Though HS is not life-threatening, it can cause debilitating pain and is strongly linked to depression and poor quality of life. People with HS can have trouble forming intimate relationships. The disease often causes its embarrassed sufferers to hide from the world.

The pain was making my patient’s work as a baggage handler challenging. At home, he was becoming more dependent on his mother to take care of him. Even sitting down could be excruciating.

After a few months of standard treatment, I put him on a more aggressive regimen of an infusion medication (infliximab, brand name Remicade) and later added an oral medication (methotrexate), both immunosuppressive drugs. His disease had improved about 80%, by his estimation, but the progress had plateaued. I wanted him to think about changing his medications to control his disease more completely, but he was hesitant to push further.

As a dermatologist who has treated dozens of patients with HS, I know that even when a particular medication works, it often feels more like luck than anything else. Sometimes in medicine, a complete resolution is just not possible and any appreciable improvement may be the focus. To some patients, 80% is good enough, but I thought it was strange how easily he accepted his condition with the remaining 20% not addressed.

Despite the effectiveness of his infusions, given the plateau, I encouraged him to try switching to a different injected medication (adalimumab, brand name Humira) that has proven useful for many HS patients.

After I convinced my patient to try the new treatment, he had to stop the previous one that merely got him to 80%. Unfortunately, not long after this change, he experienced a bad flare-up. He ended up with large wounds in his armpits and buttocks that kept him bed bound for months and took more than a year to heal. Though flares are common and this one was not necessarily caused by the new therapy, I felt intensely guilty for having pushed him to try it. Now that he was down to 20% control, I would’ve done anything to get him back to 80%.

If he were happy, even with his disease only stable but persistent, who was I to impose or suggest additional treatment? Worse, had I risked losing his trust in my care?

My patient is now stable on his original infliximab infusion therapy, but his HS still flares now and then. Yet he rarely grumbles. When I examine him at checkups, I still may find paper towels packed in his underwear, but he insists he is doing just fine.

What drove me to keep pushing is imagining what I would want if I were in his position. But maybe that’s my mistake. We all know about the Golden Rule: Do unto others as you would have them do unto you. But perhaps I should be following the Platinum Rule, conceived by Tony Alessandra, the prolific author and business leadership expert: “Treat others the way they want to be treated.”

Maybe the Platinum Rule should be the guiding principle in medicine — or at least my guiding principle.

My patient’s care is likely to remain challenging for years to come. I hope he knows I’ll stick with him, and advocate on his behalf. But I also hope I can remember to check myself when I can’t help but want to get him to 90% and to respect his autonomy. I must wield his confidence in me carefully, and only recommend what truly fits his goals.

I want him to live the life he wants and respect his judgment. If 80% better is good enough for him, it should be good enough for me.

Jules Lipoff is an assistant professor of dermatology at the University of Pennsylvania Perelman School of Medicine.

Source link

Chronic inflammatory skin diseases not linked to VTE risk, finds JAMA study

Chronic inflammatory skin diseases not linked to VTE risk, finds JAMA study Top

Source link

Access to this page has been denied.

Access to this page has been denied because we believe you are using automation tools to browse the
website.

This may happen as a result of the following:

  • Javascript is disabled or blocked by an extension (ad blockers for example)
  • Your browser does not support cookies

Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking
them from loading.

Reference ID: #e300dd20-cd04-11eb-818f-2b0fad57bfa6

Source link

Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference | Business

WILMINGTON, Del.–(BUSINESS WIRE)–Jun 12, 2021–

Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting updated data for ruxolitinib cream, an investigational topical JAK1/JAK2 inhibitor, in patients with atopic dermatitis (AD) will be presented at the upcoming 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference, held on June 13, 2021.

“Atopic dermatitis, the most common type of eczema, can be difficult to manage and can have a significant impact on patients’ lives,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. “We are pleased to be sharing new data from our Phase 3 TRuE-AD program at the RAD Virtual Conference. These data provide additional insights on the potential role ruxolitinib cream could play as a treatment option for patients living with atopic dermatitis.”

Key abstracts include:

Late-Breaking Oral and Poster Presentation

Long-Term Safety and Disease Control with Ruxolitinib Cream in Atopic Dermatitis: Results from Two Phase 3 Studies

Poster Presentations

Long-Term Safety and Disease Control with Ruxolitinib Cream in Patients with More Severe Atopic Dermatitis: Pooled Results from Two Phase 3 Studies

Long-Term Safety and Disease Control with Ruxolitinib Cream Among Patients with Atopic Dermatitis Based on Previous Medication History: Pooled Results from Two Phase 3 Studies

Predicting Reduction in Lost Productivity and Indirect Costs Among Patients with Atopic Dermatitis Treated with Ruxolitinib Cream

Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis

More information regarding the virtual conference is available on the RAD website: https://revolutionizingad.com/. Additionally, meeting abstracts will be published in the British Journal of Dermatology.

About Ruxolitinib Cream

Ruxolitinib cream is a proprietary formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib that has been designed for topical application. Ruxolitinib cream is currently in Phase 3 development for the treatment of adolescents and adults with atopic dermatitis (TRuE-AD) and vitiligo (TRuE-V). Incyte has worldwide rights for the development and commercialization of ruxolitinib cream.

About Incyte Dermatology

Incyte’s science-first approach and expertise in immunology has formed the foundation of the company. In Dermatology, the Company’s research and development efforts are focused on leveraging our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies with the potential to modulate immune pathways driving uncontrolled inflammation and help restore normal immune function.

Currently, Incyte is exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo and hidradenitis suppurativa. To learn more, visit the Dermatology section of Incyte.com.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s ongoing clinical development program for ruxolitinib cream, its TRuE-AD and TRuE-V programs and its atopic dermatitis, vitiligo and other dermatology programs generally, and whether or when ruxolitinib cream will be approved or commercially available in the U.S. or elsewhere for atopic dermatitis, vitiligo or any other indication, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain, other third-party providers and development and discovery operations; determinations made by the U.S. FDA and other regulatory authorities outside of the United States; the efficacy or safety of the Company’s products; the acceptance of the Company’s products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended March 31, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210612005013/en/

CONTACT: Media

Catalina Loveman

+1 302 498 6171

cloveman@incyte.com

Jenifer Antonacci

+1 302 498 7036

jantonacci@incyte.com

Investors

Christine Chiou

+1 302 274 4773

cchiou@incyte.com

KEYWORD: DELAWARE UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH FDA CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Incyte

Copyright Business Wire 2021.

PUB: 06/12/2021 05:01 PM/DISC: 06/12/2021 05:02 PM

http://www.businesswire.com/news/home/20210612005013/en

Copyright Business Wire 2021.

Source link

Wearing well amid challenges

From digital product launches, to remote working and daily check-ins with staff, Suzanne Moloney talks us through the challenges she faced during lockdown – and the noodles that got her through.

On the challenges of a pandemic…

From a business perspective, I’ve learned that we have an incredible, resilient, team who will work hard from any location. It is important that we can still get HidraWear wound dressings to HS [Hidradenitis Suppurativa] patients despite the pandemic and we’ve worked hard from our living rooms and kitchen to make that happen. Adapting our plans for launching HidraWear in America was by far the biggest challenge. The original launch plan included a five-week tour of the States meeting HS patient groups and clinics. That was planned for April 2020 but obviously had to be cancelled. Instead, the launch was purely digital. I’m relieved to say that HidraWear is now helping American patients as well as HS patients in the UK, Ireland and Europe.

…and the opportunities

With everyone worldwide being home, in lockdown and self-isolating, it’s meant that we have had the opportunity to engage and offer support to more HS patients online. There are amazing communities on Facebook, Reddit, Instagram and specific HS sites where patients talk to each other and look for advice. These communities can be a lifeline for HS patients who are really struggling. The pain and symptoms of HS can really take their toll on patients’ mental health.

On remote working…

We have already decided to opt for a hybrid approach for the whole team. The pandemic has proven that it’s possible to have this flexibility and still be productive.

…and motivating staff

We have a daily check in with the whole HidraWear team which we use as an opportunity to check in with one another as well as discuss our work. I sometimes send random little gifts to the team and we chat throughout the day using teams and on the phone. We definitely have lots of catching up to do when it comes to celebrating different occasions and milestones achieved. Everyone on the team by nature is highly motivated and engaged. I trust everyone to manage their time and plan their days. They always get the job done. I’m incredibly grateful for my team.

On the “new normal”…

I think that we, as a country, will go back to the way it was to a degree. Hopefully though, we have learned lessons from the pandemic that we will take forward with us. The flexibility for staff to work from home is a big one but also the importance of work-life balance for our physical and mental health. Communities have really come together, online and off, during the lockdowns and I hope that that neighbourly lifestyle will stay.

….which will feature Zoom

Both business travel and Zoom are in our future… Business travel to meet international colleagues, and in our case, national and international HS patients will definitely be back on the agenda. Zoom and video conferencing in general have proven their value for team meetings and collaboration.

On personal challenges…

Personally, my biggest challenge was where to live during the lockdowns. I am from Dublin but HidraWear is based in Galway. HidraWear is at an important stage of growth, so there hasn’t been much time for hobbies. The time saved on commuting is ploughed into the business. I did start making my own kombucha though, which is delicious, and I’ve taken a few online courses too.

…and restrictions lifting

I can’t wait to see the whole team together. We are lucky to have such a great group of people who are united in their ambition to help people with HS. I’m looking forward to getting everyone together for dinner or drinks and celebrating the missed occasions, both in terms of business, and outside the office. One of my team graduated from college this year, another moved into his new home and another became a homeowner – all big events that should have been marked with a celebration. Then the company itself has hit some big milestones. Our first product was listed on the Primary Care Reimbursement Service (PCRS) this year, and is available to patients through the medical card and drug payment scheme. We also have released three new products this year. This definitely would have warranted a party, so I look forward to celebrating with my team when we can.

On her top takeaway during the pandemic:

I love Jalan Jalan (www.jalanjalan.ie) — their noodles are addictive.

Suzanne Moloney is founder and chief executive of HidraMed Solutions which has developed a novel dressing system aimed at those suffering from the incurable skin disease, Hidradenitis Suppurativa (HS).


Business Today

Get the latest business news and commentarySIGN UP HERE

Source link

Premarket Activity For The ChemoCentryx (CCXI) Stock Today: What Is Raising It?

In premarket hours on the last check Friday, ChemoCentryx Inc. (CCXI) was up 13.52% at $13.1. In the last trading session, ChemoCentryx stock finished the session up 3.2% at $11.54. A range of $11.1208 to $11.74 was seen in CCXI stock price on the day.

ChemoCentryx stock traded 3.61 million shares on the day, a volume higher than its daily average of 1.9 million shares over 100 days. The CCXI stock has gained traction following the selection of an abstract from ChemoCentryx by a European body.

Which abstract from CCXI was selected?

The biopharmaceutical company ChemoCentryx is developing new medicines for cancer and inflammatory diseases. By using chemokines and chemoattractants, CCXI targets the discovery, development, and commercialization of oral therapies. Avacopan (CCX168) is the lead drug candidate of CCXI. ChemoCentryx completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the US Food and Drug Administration (FDA).

ChemoCentryx this week has released presentations highlighting findings from its Phase III ADVOCATE and Phase II ACCOLADE and LUMINA-1 trials.

  • CCXI’s presentations were a part of the ERA-EDTA (European Renal Association – European Dialysis and Transplant Association) annual meeting, which was held virtually from June 5 to 8, 2021, in Berlin, Germany.
  • CCXI is also working on avacopan as a treatment for C3 glomerulopathy (C3G) and hidradenitis suppurativa (HS) patients.
  • CCXI’s avacopan has been designated an orphan drug by the FDA for ANCA-associated vasculitis and C3G.
  • The European Commission awarded the company orphan medicinal product designations for avacopan, a medication used in the treatment of microscopic polyangiitis and granulomatosis with polyangiitis caused by ANCA.

CCXI’s potential:

ChemoCentryx (CCXI) discovered and developed avacopan, and it is the company that owns and retains the commercial rights in the United States. Vifor Pharma has exclusive rights to commercialize avacopan in markets outside of the United States under the Kidney Health Alliance between Vifor Pharma and CCXI.

Source link

Global Hidradenitis Suppurativa Treatment Market Is Thriving Worldwide With Top Growing Companies -ALLERGAN, AstraZeneca, GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Mylan N.V – KSU

All the data of research and analysis in the large scale XYZ business document are mapped in an actionable model with strategic recommendations from the experts. Client’s needs are understood well by experts leveraging their expertise and strong knowledge base to identify and evaluate competition and chalk out strategic programs, with short-term goals and long-term objectives. This market survey report recognizes and analyses the emerging trends along with major drivers, challenges and opportunities in the ABC industry. The world class XYZ report provides wide-ranging statistical analysis of the market’s continuous positive developments, capacity, production, production value, cost/profit, supply/demand and import/export.

Global hidradenitis suppurativa treatment market is rising gradually with a substantial CAGR in the forecast period of 2019-2026. The global hidradenitis suppurativa treatment market is supposed to grow faster during the forecast period as a large number of ongoing clinical trial and introduction of new treatment options.

Get Sample Copy Of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hidradenitis-suppurativa-treatment-market

Few of the major competitors currently working in the global hidradenitis suppurativa treatment market are AbbVie Inc., Novartis AG, TARGET PharmaSolutions, Inc., Eisai Co., Ltd, Abbott, ALLERGAN, AstraZeneca, GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Mylan N.V., LEO Pharma A/S, Zydus Cadila, among others.
Market Drivers
    • Prevailing cases of various skin disorders will drive the growth of this market
    • Ongoing clinical trials along with introduction of new treatment options will boost the market growth
    • Growing investment in R&D activities along with technological advancement can also boost the market growth
  • Environmental changes due to global warming has increased the skin diseases and is contributing as one of the growth factor

Market Restraints

    • A weak pipeline of drugs restrains the growth of market as most of drugs are in phase II clinical trials indicating a less chance of approval
    • High cost of therapy along with chances of side-effects can also hamper the market growth
  • Development of drug resistance to many agents used for treatment of Hidradenitis suppurativa can impede the growth of this market also disturbs the market growth

Insights of the report

  1. Market Penetration: Comprehensive information on the product portfolios of the top players in the Hidradenitis Suppurativa Treatment market.
  2. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Hidradenitis Suppurativa Treatment market.
  3. Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.
  4. Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.
  5. All the Challenges and growth opportunities in the Hidradenitis Suppurativa Treatment market along with the market drivers and restrains.

Inquiry For Customize Report With Discount at : https://www.databridgemarketresearch.com/toc/?dbmr=global-hidradenitis-suppurativa-treatment-market

Segmentation: Global Hidradenitis Suppurativa Treatment Market

By Clinical Stages

  • Hurley stage 1
  • Hurley stage 2
  • Hurley stage 3

By Treatment

  • Medication
  • Surgery
  • Others

By Route of Administration

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channels

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others

By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Get Full Table Of content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hidradenitis-suppurativa-treatment-market

Key points to focus in the report

    1. Key trends in the market place
    2. Major players and brands
    3. Drivers and restrains of the market
    4. Major players and brands
    5. Historical and current market size and projection up to 2026.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475

Source link

Adalimumab Biosimilar Market Insight Report 2021 – ResearchAndMarkets.com

DUBLIN–()–The “Adalimumab – Biosimilar Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Adalimumab- Biosimilar Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Adalimumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Adalimumab Biosimilars: Marketed Drugs

Abrilada: Pfizer

Abrilada is an FDA-approved biosimilar version of adalimumab. Abrilada (adalimumab-afzb) injection is supplied as a sterile, preservative-free solution for subcutaneous administration. The drug product is supplied as either a single-dose prefilled pen (Abrilada pen), as a single-dose 1 mL prefilled glass syringe, or as a single-dose institutional use vial. Enclosed within the pen is a single-dose 1 mL prefilled glass syringe. Though approved, it is not yet marketed in the US like several other manufacturers of approved biosimilar versions of adalimumab, Pfizer has signed a licensing agreement with AbbVie; under the agreement, Samsung would be able to launch the drug in November 2023.

In December 2019, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of Amsparity as a biosimilar to Humira (adalimumab) for the treatment of certain patients with RA, juvenile idiopathic arthritis, axial spondyloarthritis, PsA, psoriasis, hidradenitis suppurativa, Crohn’s disease, UC, uveitis, and pediatric plaque psoriasis.

Qletli: Bio-Thera Solutions

Qletli is an anti-TNF- ? monoclonal antibody. QLETLI binds specifically to soluble and membrane bound TNF-? and blocks its interaction with the p55 and p75 cell surface TNF receptors, effectively neutralizing TNF-? bioactivity. Bio-Thera Solutions has received approval from the country’s National Medical Products Administration (NMPA) for Qletli, a biosimilar to AbbVie’s Humira (adalimumab). It is the first Humira biosimilar approved in China. The drug secured approval for all eligible indications of Humira, including rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.

Adalimumab Biosimilars: Emerging Drugs

AVT02: Innovent Biologics

AVT02 is a monoclonal antibody (mAb) and a proposed biosimilar to Humira (adalimumab). It is being developed for the treatment plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, crohn’s disease, ulcerative colitis. AVT02 acts as immunosuppressants and tumour necrosis factor alpha inhibitors. In November 2020, Alvotech announced that its has filed a Biologics License Application (BLA) for AVT02 to the U.S. Food and Drug Administration (FDA), which has been accepted for review. The FDA is expected to decide on the filing in September 2021. Additionally, the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for AVT02 with an EMA decision anticipated in the fourth quarter of 2021.

MYL-1401A: Mylan

MYL-1401A is an anti-TNF monoclonal antibody. This tumor necrosis factor inhibitor is a proposed biosimilar of HUMIRA (adalimumab). MYL-1401A is a recombinant human IgG1 monoclonal antibody and is being evaluated as an injectable therapy for the treatment of rheumatoid arthritis and plaque psoriasis. Mylan has completed Phase III multicenter, double-blind, randomized, 2-arm, parallel-group, equivalence study, evaluating efficacy and safety similarity of MYL-1401A compared with Humira in subjects with moderate-to-severe chronic plaque psoriasis.

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Adalimumab Biosimilars?
  • How many Adalimumab biosimilars are developed by each company?
  • How many emerging biosimilars are in mid-stage, and late-stage?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Adalimumab biosimilars therapeutics?
  • What are the clinical studies going on for Adalimumab biosimilars and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • BioXpress Therapeutics
  • ISU Abxis
  • Zydus Cadila
  • Tanvex Biopharma
  • PlantPraxis
  • Gene Techno Science
  • Genor Biopharma
  • Meiji Seika Pharma
  • Synermore Biologics
  • Prestige BioPharma
  • Oncobiologics
  • LG Chem
  • Mylan
  • Celltrion
  • Zhejiang Hisun Pharmaceuticals
  • Alvotech
  • Biocad
  • Boehringer Ingelheim
  • Biogen
  • Emcure Pharmaceuticals
  • Hetero
  • Fresenius Kabi
  • Innovent Biologics
  • Sandoz
  • Amgen
  • Bio-Thera Solutions
  • Pfizer

Key Products

  • BX 2922
  • ISU202
  • Adaly
  • TX17
  • AMAB
  • GBS 005
  • GB 232
  • DMB-3113
  • SYN-060
  • PBP 1502
  • ONS-3010
  • LBAL
  • MYL 1401A
  • CT-P17
  • HS 016
  • AVT-02
  • BCD 057
  • Cyltezo
  • Imraldi
  • Envira
  • Mabura
  • IDACIO (adalimumab)
  • SULINNO
  • Halimatoz
  • Solymbic
  • Qletli
  • Abrilada

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/20e2ie

Source link

Hidradenitis Suppurativa Market, Epidemiology and Market Forecast-2030

Hidradenitis Suppurativa Market, Epidemiology and Market Forecast-2030

“DelveInsight Business Research LLP”

DelveInsight’s ‘Hidradenitis Suppurativa Market Insights, Epidemiology and Market Forecast-2030’ report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.

Hidradenitis Suppurativa Market

DelveInsight’s ‘Hidradenitis Suppurativa Market’ report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan 

The Hidradenitis Suppurativa market report provides current treatment practices, emerging drugs, Hidradenitis Suppurativa market share of the individual therapies, current and forecasted Hidradenitis Suppurativa market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hidradenitis Suppurativa treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

 

Hidradenitis Suppurativa Market Outlook

The Hidradenitis Suppurativa market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Hidradenitis Suppurativa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of Hidradenitis Suppurativa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Hidradenitis Suppurativa market in the 7MM is expected to change in the study period 2017–2030.

The therapeutic market of Hidradenitis Suppurativa in seven major markets is expected to generate USD 798 million in 2017 and will increase in the study period 2017–2030.

 

Hidradenitis Suppurativa Epidemiology

Advertisement. Scroll to continue reading.

 

The Hidradenitis Suppurativa epidemiology division provide the insights about historical and current Hidradenitis Suppurativa patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The total diagnosed incident cases of Hidradenitis Suppurativa (HS) patients were found to be more in females than in males in 7MM during the study period i.e. 2017–2030.

 

The disease epidemiology covered in the report provides historical as well as forecasted Hidradenitis Suppurativa epidemiology [segmented as Total Prevalent Patient Population, Diagnosed Prevalent Patient Population, Age-specific Diagnosed Prevalent Patient Population, Gender-specific Diagnosed Prevalent Patient Population, Stage-Specific (Severity-specific) Prevalent Population, and Treated Prevalent Cases of HS] scenario of Hidradenitis Suppurativa in 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017 to 2030.

 

Country Wise- Hidradenitis Suppurativa Epidemiology

The epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom) and Japan.

  

Scope of the Report

Advertisement. Scroll to continue reading.

 

  • The report covers the descriptive overview of Hidradenitis Suppurativa, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Hidradenitis Suppurativa epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hidradenitis Suppurativa are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hidradenitis Suppurativa market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hidradenitis Suppurativa market

 

Reasons to buy

 

  • The report will help in developing business strategies by understanding trends shaping and driving the Hidradenitis Suppurativa market
  • To understand the future market competition in the Hidradenitis Suppurativa market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Hidradenitis Suppurativa in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Hidradenitis Suppurativa market
  • To understand the future market competition in the Hidradenitis Suppurativa market

Media Contact
Company Name: DelveInsight
Contact Person: Media Relations
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Source link

APAC, Europe, America region to materialize major revenue contributor for Tumor Necrosis Factor (TNF) Inhibitor Drugs market through 2026

APAC, Europe, America region to materialize major revenue contributor for Tumor Necrosis Factor (TNF) Inhibitor Drugs market through 2026
Category: #business |  
By Admin |  
Published: 23 hours ago

 |  Product ID: 2203792 | 


APAC, Europe, America region to materialize major revenue contributor for  Tumor Necrosis Factor (TNF) Inhibitor Drugs  market through 2026

The Global “ Tumor Necrosis Factor (TNF) Inhibitor Drugs Market” 2021 Research report produces information with reference to market size, share, trends, growth, cost structure, capacity, revenue, and forecast 2026. This report also contains the general and comprehensive study of the Tumor Necrosis Factor (TNF) Inhibitor Drugs market with all its aspects influencing the growth of the market. This report is a full-scale quantitative survey of the Tumor Necrosis Factor (TNF) Inhibitor Drugs industry and provides data for building strategies to expand the market growth and effectiveness.

Executive summary:

The research report on Tumor Necrosis Factor (TNF) Inhibitor Drugs market comprises a thorough evaluation of the past and present business scenario to deliver a conclusive overview of the industry’s growth patterns over 2021-2026. It casts light on the sizes and shares the markets and sub-markets, emphasizing on the primary growth stimulants, obstacles, and lucrative prospects impacting the business dynamics.

Request Sample Copy of this Report @ https://www.business-newsupdate.com/request-sample/142733

As per expert analysts, Tumor Necrosis Factor (TNF) Inhibitor Drugs market is predicted to record notable growth over the study period, bolstering at XX% CAGR throughout.

The research literature also includes actionable insights into the competitive landscape, stressing on the well-known strategies employed by major contenders to enjoy strong profit margins in the upcoming years. In addition, the document answers all queries relating to implications of COVID-19 pandemic.

Market snapshot:

Geographical outlook:

  • Key regional contributors of Tumor Necrosis Factor (TNF) Inhibitor Drugs market are Americas, APAC, Europe, Middle East & Africa.
  • Market share in relation to the consumption volume and value of each regional market is taken into account.
  • Role of key regions to the overall industry progression is computed.

Product landscape outline:

  • The document segments the product terrain of Tumor Necrosis Factor (TNF) Inhibitor Drugs market into Humira , Enbrel , Remicade , Simponi/Simponi Aria , Cimzia and Biosimilars.
  • Industry share of every product segment is given.
  • Data relating to overall revenue generated and total sales amassed by every product type are provided.

Application spectrum summary:

  • The application spectrum of Tumor Necrosis Factor (TNF) Inhibitor Drugs market is bifurcated into Rheumatoid Arthritis , Psoriasis , Psoriatic Arthritis , Crohn?s Disease , Ulcerative Colitis , Ankylosing Spondylitis , Juvenile Idiopathic Arthritis , Hidradenitis Suppurativa and Others.
  • Estimates for consumption volume and value of every application scope are supported with stats.
  • Approximations for each application segment’s market share over the analysis period are enumerated as well.

Competitive arena overview:

  • Top companies in Tumor Necrosis Factor (TNF) Inhibitor Drugs market is AbbVie Inc. , Amgen Inc. , UCB S.A. , Novartis International AG , Johnson & Johnson Services, Inc. , Pfizer, Inc. , Merck & co. and Inc.
  • The document offers a business overview of all the mentioned players.
  • Records of net revenue, pricing models, operating profits, sales, and other financial attributes of each organization are systematically sorted.
  • Manufacturing facilities and operating areas of the listed players are given.
  • Up-to-date data on partnerships, associations, and new entrants in the domain are also presented in the study.

Key Questions Answered this Report are:

  • What will be the Tumor Necrosis Factor (TNF) Inhibitor Drugs market scale and growth rate in the estimate years from 2021 to 2026?
  • What are the significant driving factors of the Tumor Necrosis Factor (TNF) Inhibitor Drugs market?
  • What are the opportunity and challenges in front of the market?
  • Who are the key vendors in the Tumor Necrosis Factor (TNF) Inhibitor Drugs market?
  • What are the trending features manipulating market equity?
  • What are the key products of Porter’s five forces model?
  • what are the global prospects for expanding the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market?

Reasons why you should buy this report

  • Understand the current and future of the Tumor Necrosis Factor (TNF) Inhibitor Drugs Market in both developed and emerging markets.
  • The report assists in realigning the business strategies by highlighting the Tumor Necrosis Factor (TNF) Inhibitor Drugs business priorities.
  • The report throws light on the segment expected to dominate the Tumor Necrosis Factor (TNF) Inhibitor Drugs industry and market.
  • Forecasts the regions expected to perceive Rapid growth.
  • The latest developments in the Tumor Necrosis Factor (TNF) Inhibitor Drugs industry and details of the industry leaders along with their market share and strategies.
  • Saves time on the entry level research as the report contains important data concerning about growth, size, leading players and segments of the industry.
  • Save and cut time carrying out entry-level research by distinguishing the growth, size, leading players and segments within the global Market.

Request Customization on This Report @ https://www.business-newsupdate.com/request-for-customization/142733

Source link